Add Yahoo as a preferred source to see more of our stories on Google. For the first time in two decades, the FDA has approved a new class of non-opioid pain medication, offering an alternative to ...

Viatris VTRS announced that the FDA has accepted the new drug application (NDA) for review for MR-107A-02, a fast-acting ...

VERTANICAL today announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation to VER-01, the company's first-in-class non-opioid investigational treatment for ...

The Food and Drug Administration has approved a new pain medication that could take the place of opioids for those experiencing moderate to severe acute pain. The drug is Journavx, or the generic name ...

Please provide your email address to receive an email when new articles are posted on . Safety labels will now explain risks associated with long-term use. Data from a pair of postmarketing ...

As opioid-related overdoses killed almost 50,000 Americans in 2017, the US Food and Drug Administration (FDA) on Thursday began soliciting comments on a plan to require special packaging for certain ...

The growing problem of misuse and abuse of extended-release and long-acting (ER/LA) opioid medications has resulted in a serious public health crisis of addiction, overdose, and death. In 2009, there ...

The FDA is requiring manufacturers of opioid pain medications to update safety labels to better emphasize risks linked to their long-term use, the agency announced in a new Drug Safety Communication.

For the first time in two decades, the FDA has approved a new class of non-opioid pain medication, offering an alternative to addictive opioids for patients seeking pain relief. The drug, suzetrigine, ...